98,236 Shares of Arcutis Biotherapeutics, Inc. $ARQT Bought by Fulcrum Asset Management LLP

Posted by George Bondi on Nov 11th, 2026

Fulcrum Asset Management LLP bought a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) in the third quarter, HoldingsChannel.com reports. The fund bought 98,236 shares of the company’s stock, valued at approximately $2,628,000.

A number of other large investors also recently modified their holdings of ARQT. Montanova Capital LLC grew its stake in shares of Arcutis Biotherapeutics by 0.9% during the second quarter. Montanova Capital LLC now owns 12,437,000 shares of the company’s stock valued at $326,098,000 after purchasing an additional 110,000 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Arcutis Biotherapeutics in the second quarter valued at approximately $276,502,000. Bank of America Corp DE acquired a new stake in shares of Arcutis Biotherapeutics in the second quarter valued at approximately $78,330,000. Janus Henderson Group PLC raised its position in Arcutis Biotherapeutics by 1.3% in the 1st quarter. Janus Henderson Group PLC now owns 1,854,566 shares of the company’s stock worth $43,684,000 after purchasing an additional 24,505 shares during the last quarter. Finally, Jupiter Topco LLC bought a new position in Arcutis Biotherapeutics in the 2nd quarter worth approximately $36,989,000.

Insider Buying and Selling at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, Director Terrie Curran sold 38,200 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $25.03, for a total transaction of $956,146.00. Following the sale, the director directly owned 23,526 shares in the company, valued at approximately $588,855.78. This trade represents a 61.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Patrick Burnett sold 943 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $31.86, for a total transaction of $30,043.98. Following the completion of the transaction, the executive vice president directly owned 116,649 shares in the company, valued at approximately $3,716,437.14. The trade was a 0.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 108,932 shares of company stock worth $3,158,225 in the last quarter. Company insiders own 9.40% of the company’s stock.

Arcutis Biotherapeutics Price Performance

Arcutis Biotherapeutics stock opened at $27.39 on Wednesday. The firm has a market capitalization of $3.46 billion, a P/E ratio of 130.43 and a beta of 1.66. The business has a 50-day moving average of $27.28 and a 200-day moving average of $25.37. The company has a current ratio of 2.92, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42. Arcutis Biotherapeutics, Inc. has a 1 year low of $19.30 and a 1 year high of $34.80.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.12). The firm had revenue of $143.92 million during the quarter, compared to analyst estimates of $142.59 million. Arcutis Biotherapeutics had a return on equity of 14.18% and a net margin of 5.88%. On average, equities analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

ARQT has been the topic of several research reports. Morgan Stanley upped their price objective on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Weiss Ratings raised Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 29th. Jefferies Financial Group reissued a “buy” rating and issued a $39.00 target price on shares of Arcutis Biotherapeutics in a research note on Thursday, October 8th. Guggenheim boosted their target price on Arcutis Biotherapeutics from $38.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. Finally, Needham & Company LLC set a $40.00 price target on Arcutis Biotherapeutics in a research note on Thursday, November 5th. Eight equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $39.75.

Check Out Our Latest Stock Report on ARQT

Arcutis Biotherapeutics Profile

(Free Report)

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. market and continues to develop medicines for dermatologic conditions. Its leadership is headed by President and Chief Executive Officer Frank Watanabe.